Comparative Efficacy and Safety of Chinese Patent Medicines of Iron Deficiency Anemia During Pregnancy: A Network Meta-analysis

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2024 Jul 10

PMID 38983402

Authors

Jia-Chen Zou

Xian-Ling Jia

Hai-Xia Wang

Ying-Jie Su

Jing-Yu Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Iron deficiency anemia (IDA) is a prevalent nutritional disorder during pregnancy. Clinical studies indicate that incorporating Chinese patent medicines (CPMs) with oral iron (OI) in treating IDA in pregnancy can reduce adverse effects and improve clinical outcomes. Nonetheless, the comparative efficacy of different CPMs remains unclear.

Aim: To assess the safety and effectiveness of different CPMs for treating IDA during pregnancy using network meta-analysis.

Methods: We conducted a search for randomized controlled trials (RCTs) that combined CPM and OI for IDA treatment in pregnancy, spanning from 2013 to the present. Data analysis was performed using Rev Man 5.3 and Stata 14.0 on literature that satisfied the quality criteria.

Results: The analysis included 45 RCTs, encompassing 4422 pregnant patients with IDA. Six CPMs were examined, including Shengxuebao Mixture, Shengxuening Tablets (SXN), Yiqi Weixue CPMs (YQWX), Jianpi Shengxue CPMs (JPSX), Yiqi Buxue Tablets, and Compound Hongyi Buxue Oral Liquid (FFHY). Findings indicated that FFHY + OI significantly improved the clinical effective rate. SXN + OI was most effective in boosting red blood cells counts and hemoglobin levels. YQWX + OI showed superior results in improving serum ferritin, and SXN + OI was most effective in increasing serum iron levels. JPSX + OI was optimal in reducing adverse pregnancy outcomes, while YQBX + OI effectively minimized adverse events. A cluster analysis suggested that SXN + OI could be the potentially optimal therapeutic regimen for IDA in pregnancy.

Conclusion: This study demonstrates that the combination of OI with CPMs offers better outcomes than OI alone. Based on clinical efficacy and other measured outcomes, SXN + OI emerges as the most effective treatment modality for improving the health of pregnant patients with IDA.

References

Lee A, Okam M . Anemia in pregnancy. Hematol Oncol Clin North Am. 2011; 25(2):241-59, vii. DOI: 10.1016/j.hoc.2011.02.001. View

Neogi S, Devasenapathy N, Singh R, Bhushan H, Shah D, Divakar H . Safety and effectiveness of intravenous iron sucrose versus standard oral iron therapy in pregnant women with moderate-to-severe anaemia in India: a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Glob Health. 2019; 7(12):e1706-e1716. DOI: 10.1016/S2214-109X(19)30427-9. View

Moreira A, Mesquita G, Gomes M . Ferritin: An Inflammatory Player Keeping Iron at the Core of Pathogen-Host Interactions. Microorganisms. 2020; 8(4). PMC: 7232436. DOI: 10.3390/microorganisms8040589. View

Camaschella C, Nai A, Silvestri L . Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020; 105(2):260-272. PMC: 7012465. DOI: 10.3324/haematol.2019.232124. View

Sangkhae V, Nemeth E . Placental iron transport: The mechanism and regulatory circuits. Free Radic Biol Med. 2018; 133:254-261. PMC: 7059975. DOI: 10.1016/j.freeradbiomed.2018.07.001. View

Cumpston M, Li T, Page M, Chandler J, Welch V, Higgins J . Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019; 10:ED000142. PMC: 10284251. DOI: 10.1002/14651858.ED000142. View

Wong L, Smith S, Gilstrop M, Derman R, Auerbach S, London N . Safety and efficacy of rapid (1,000 mg in 1 hr) intravenous iron dextran for treatment of maternal iron deficient anemia of pregnancy. Am J Hematol. 2016; 91(6):590-3. DOI: 10.1002/ajh.24361. View

Nair M, Knight M, Kurinczuk J . Risk factors and newborn outcomes associated with maternal deaths in the UK from 2009 to 2013: a national case-control study. BJOG. 2016; 123(10):1654-62. PMC: 5021205. DOI: 10.1111/1471-0528.13978. View

Benson A, Shatzel J, Ryan K, Hedges M, Martens K, Aslan J . The incidence, complications, and treatment of iron deficiency in pregnancy. Eur J Haematol. 2022; 109(6):633-642. PMC: 9669178. DOI: 10.1111/ejh.13870. View

10.

Daru J, Zamora J, Fernandez-Felix B, Vogel J, Oladapo O, Morisaki N . Risk of maternal mortality in women with severe anaemia during pregnancy and post partum: a multilevel analysis. Lancet Glob Health. 2018; 6(5):e548-e554. DOI: 10.1016/S2214-109X(18)30078-0. View

11.

. Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998; 47(RR-3):1-29. View

12.

. Anemia in Pregnancy: ACOG Practice Bulletin, Number 233. Obstet Gynecol. 2021; 138(2):e55-e64. DOI: 10.1097/AOG.0000000000004477. View

13.

Pynaert I, Delanghe J, Temmerman M, De Henauw S . Iron intake in relation to diet and iron status of young adult women. Ann Nutr Metab. 2007; 51(2):172-81. DOI: 10.1159/000103278. View

14.

Birhanu Z, Chapleau G, Ortolano S, Mamo G, Martin S, Dickin K . Ethiopian women's perspectives on antenatal care and iron-folic acid supplementation: Insights for translating global antenatal calcium guidelines into practice. Matern Child Nutr. 2018; 14 Suppl 1. PMC: 6866194. DOI: 10.1111/mcn.12424. View

15.

VARDE K . TREATMENT OF 300 CASES OF IRON DEFICIENCY OF PREGNANCY BY TOTAL DOSE INFUSION OF IRON-DEXTRAN COMPLEX. J Obstet Gynaecol Br Commonw. 1964; 71:919-22. DOI: 10.1111/j.1471-0528.1964.tb04380.x. View

16.

Tolkien Z, Stecher L, Mander A, Pereira D, Powell J . Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015; 10(2):e0117383. PMC: 4336293. DOI: 10.1371/journal.pone.0117383. View

17.

Ataide R, Fielding K, Pasricha S, Bennett C . Iron deficiency, pregnancy, and neonatal development. Int J Gynaecol Obstet. 2023; 162 Suppl 2:14-22. DOI: 10.1002/ijgo.14944. View

18.

Mistry R, Jones A, Pednekar M, Dhumal G, Dasika A, Kulkarni U . Antenatal tobacco use and iron deficiency anemia: integrating tobacco control into antenatal care in urban India. Reprod Health. 2018; 15(1):72. PMC: 5932801. DOI: 10.1186/s12978-018-0516-5. View

19.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . [The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsDeclaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas]. Rev Panam Salud Publica. 2023; 46:e112. PMC: 9798848. DOI: 10.26633/RPSP.2022.112. View

20.

Haider B, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi W . Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. BMJ. 2013; 346:f3443. PMC: 3689887. DOI: 10.1136/bmj.f3443. View